跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SITAGLIPTIN-METFORMIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SITAGLIPTIN-METFORMIN
Authorized
STANDARD
SITAGLIPTIN-METFORMIN
sivem pharmaceuticals ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2f36701653e111c1
Company
sivem pharmaceuticals ulc
Type
Standard
Approval Details
Approval Id
2f36701653e111c1
Drug Approval Canada Name
SITAGLIPTIN-METFORMIN
Product Name
SITAGLIPTIN-METFORMIN
Status
Marketed
Status Date
2023-02-06
Original Market Date
2023-02-06
Din
02529165
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.05
Atc Original
A10BD07 METFORMIN AND SITAGLIPTIN
Atc Name
a 10 bd 07
Aig Number
0252656002
Company Name
sivem pharmaceuticals ulc
Company Address
4705 Dobrin Street, Saint-Laurent, Quebec, Canada, H4R 2P7
Active Ingredients
METFORMIN HYDROCHLORIDE
850 MG
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2f36701653e111c1
Type
Standard
Back to Health Canada Approvals